Implementing the NYU Electronic Patient Visit Assessment (ePVA) for Head and Neck Cancer In Rural and Urban Populations

Last updated: July 12, 2024
Sponsor: The University of Texas Health Science Center, Houston
Overall Status: Active - Recruiting

Phase

N/A

Condition

Head And Neck Cancer

Human Papilloma Virus (Hpv)

Nasopharyngeal Cancer

Treatment

Usual Care

NYU Electronic Patient Visit Assessment (ePVA)

Clinical Study ID

NCT06030011
HSC-SN-23-0784
  • Ages > 18
  • All Genders

Study Summary

The PI and the research team developed the New York University (NYU) Electronic Patient Visit Assessment (ePVA) for head and neck cancer (HNC) as a patient-reported outcome measure (PRO) for the early detection of uncontrolled symptoms. The ePVA is digital patient-reported symptom monitoring system, providing actionable information at point-of-care that enables clinicians to provide real-time interventions. The study aims to advance the science of cancer care delivery by testing the effectiveness of the ePVA as a digital patient-reported monitoring system for patients with HNC in real-world settings and identify implementation strategies that optimize the effectiveness of the ePVA in diverse rural and urban settings. The study hypothesis is that participants assigned to the ePVA arm will have better swallowing, taste and smell, and social function than participants assigned to usual care arm at 4 weeks after completing radiation therapy.

Eligibility Criteria

Inclusion

Inclusion Criteria (Patient Participants):

  • Individuals with histologically diagnosed head and neck cancer (HNC) undergoing curative radiation therapy with or without chemotherapy

  • English or Spanish speaking

Inclusion Criteria (Clinician Participants):

  • Clinicians (i.e., physicians, nurses, dentists, physician assistants, social workers, nutritionists, speech swallow therapists) caring for patients with head and neck cancer at the participating institutions

Exclusion Criteria (Patient and Clinician Participants):

  • Any medical condition that could limit the participant's ability to provide informed consent and complete the questionnaires.

Study Design

Total Participants: 270
Treatment Group(s): 2
Primary Treatment: Usual Care
Phase:
Study Start date:
June 25, 2024
Estimated Completion Date:
August 31, 2028

Connect with a study center

  • University of Kansas Cancer Center

    Kansas City, Kansas 66160
    United States

    Active - Recruiting

  • NYU Langone Perlmutter Cancer Center

    New York, New York 10016
    United States

    Active - Recruiting

  • NYU Meyers College of Nursing

    New York, New York 10010
    United States

    Site Not Available

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania 19111
    United States

    Site Not Available

  • UTHealth Houston Cizik School of Nursing

    Houston, Texas 77030
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.